clinical trial · NCT05340257
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
GlaxoSmithKline·phase2·withdrawn
Infections, BacterialAugmentin ES
brief summary
The purpose of this study is to evaluate the pharmacokinetics, safety or tolerability through treatment emergent adverse event (TEAE) and to explore primary and secondary clinical response of treatment with Augmentin ES in pediatric population presenting with CAP and ABRS in Brazil.
started
Oct 14, 2023
primary completion
Jul 8, 2024
completion
Jul 8, 2024
last updated
Mar 28, 2025
official title
An Open Label, Single Arm Study, to Evaluate the Pharmacokinetics and Safety of Augmentin Extra Strength (ES)-600 Suspension in Children Presenting With Community Acquired Pneumonia (CAP) and Acute Bacterial Rhinosinusitis (ABRS) in Brazil
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol